Pacific Biosciences 株価情報 (NASDAQ: PACB)

最新ニュース Pacific Biosciences (NASDAQ:PACB) 株価情報

Pacific Biosciences

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

Pacific Biosciences of California, Inc. - Common Stock

Pacific Biosciences of California Inc

Canaccord Genuity analyst Kyle Mikson maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Buy and maintains $3 price target.

News

Price Target

Analyst Ratings

PACB

Canaccord Genuity Maintains Buy on Pacific Biosciences, Maintains $3 Price Target

Pacific Biosciences of California Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) on Wednesday announced preliminary revenue of $36.9 million versus a <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $33.49 million</a>.
The company said the first quarter met expectations, despite impacts from ongoing uncertainty in NIH funding in the United States and broader economic headwinds <a href="https://www.benzinga.com/pressreleases/25/04/g44710496/pacbio-announces-preliminary-first-quarter-2025-revenue-and-reiterates-2025-revenue-guidance-of-15" target="_blank" rel="noreferrer noopener">affecting the industry</a>.
Vega system orders accelerated in the first quarter compared to the fourth quarter of 2024. The combination of system capability and its attractive price point enabled purchases from new and existing customers.
The sequencing solutions company said preliminary consumable revenue reached a company record. Annualized Revio pull-through per system was approximately $236,000. That&#8217;s in line with the company&#8217;s expectations in the low to mid $200,000s range.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44716951/enphase-rolls-out-scalable-grid-ready-iq-battery-5p-in-poland-with-15-year-warranty" rel="noreferrer noopener">Enphase Rolls Out Scalable, Grid-Ready IQ Battery 5P in Poland With 15-Year Warranty</a>
&#8220;&#8230;The Vega launch is progressing well, attracting more customers to HiFi sequencing and is expanding our addressable applications. While the funding and general macroeconomic environment is having an impact on our ability to place more instruments, particularly Revio systems at academic customers, we are encouraged by the consistent Revio utilization and annualized consumable pull-through, which remain in line with our expectations,&#8221; said Christian Henry, President and CEO of PacBio.
&#8220;We believe we are on pace to achieve the financial goals we set earlier this year. However, given the persistent uncertainty surrounding academic and NIH funding, along with the introduction of new tariffs, we are taking strategic steps to reduce spending and reinforce our plan to reach positive cash flow by the end of 2027.&#8221;
The company says it will focus on three key priorities:
<ul>
<li>Accelerating the adoption of HiFi sequencing,</li>
<li>Investing in initiatives that are targeted to improve gross margin.</li>
<li>Advancing innovation in long-read sequencing portfolio to enhance platform scalability and reduce costs.</li>
</ul>
PacBio is also restructuring commercial organization to streamline management and improve sales force efficiency.
Guidance: The company reiterates its previous 2025 revenue forecast of $155 million to $170 million versus the consensus of $161.51 million.
<ul>
<li>Growth in Vega shipments offset a year-over-year decline in Revio system shipments, with annualized pull-through per Revio system in the low to mid $200,000 range.</li>
<li>2025 non-GAAP gross margin to be between 35% and 40%.</li>
</ul>
In response to ongoing market uncertainty, PacBio is executing a plan to reduce headcount across all functions and non-headcount-related expenses to lower its annualized non-GAAP operating expense run-rate by $45 million to $50 million by year-end, compared to its prior guidance of $270 million to $280 million. Its ending cash and investments balance will also be higher than the previous guidance of approximately $260 million.
Price Action: PACB stock is up 8.75% at $1.31 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44715789/fda-approves-bristol-myers-opdivo-plus-yervoy-combo-for-untreated-colorectal-cancer-patients" target="_blank" rel="noreferrer noopener">FDA Approves Bristol Myers&#8217; Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients</a></li>
</ul>

Earnings

Guidance

Health Care

Movers

Trading Ideas

General

Sequencing Company PacBio Cuts Costs Amid Uncertainty Around NIH Funding And New Tariffs

U.S. stocks were higher, with the Dow Jones index surging over 300 points on Wednesday.
Shares of The Simply Good Foods Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMPL#NASDAQ">SMPL</a>) rose sharply during Wednesday's session following better-than-<a href="https://in.benzinga.com/25/04/44709659/why-packaged-food-company-simply-good-foods-stock-is-gaining-today">expected quarterly results</a>.
The company, led by CEO Geoff Tanner, reported second-quarter FY25 sales growth of 15% year-on-year to $359.65 million. It beat the analyst consensus estimate of $354.4 million. Adjusted EPS of 46 cents beat the consensus estimate of 40 cents.
The Simply Good Foods shares jumped 9.4% to $36.32 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) shares jumped 20% to $1.4399 after the company announced preliminary first quarter revenue and reiterated 2025 revenue guidance of $155 million to $170 million.</li>
<li>Peabody Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTU#NYSE">BTU</a>) gained 14.4% to $12.86. Shares of coal stocks traded higher after President Trump signed an executive order aimed at boosting the coal industry.</li>
<li>Nutex Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) rose 12.7% to $95.75. Maxim Group analyst Anthony Vendetti maintained Nutex Health with a Buy and raised the price target from $75 to $100.</li>
<li>Kura Sushi USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRUS#NASDAQ">KRUS</a>) climbed 11.9% to $46.40. Kura Sushi USA posted downbeat results for its second quarter. The company also said it sees FY25 total sales of $275 million to $279 million, versus market estimates of $280.741 million</li>
<li>IAMGOLD Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) shares gained 11.5% to $6.48. Shares of precious metals stocks traded higher amid strength in gold and silver. Trade war concerns and macro uncertainty could lift demand for safe-haven assets.</li>
<li>Harmony Gold Mining Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMY#NYSE">HMY</a>) rose 11.1% to $14.40 amid strength in gold and silver. Trade war concerns and macro uncertainty could lift demand for safe-haven assets.</li>
<li>AngloGold Ashanti plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>) jumped 10% to $36.46. Shares of precious metals stocks traded higher amid strength in gold and silver. Trade war concerns and macro uncertainty could lift demand for safe-haven assets.</li>
<li>Coeur Mining, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDE#NYSE">CDE</a>) rose 8% to $5.20. Shares of precious metals stocks traded higher amid strength in gold and silver. Trade war concerns and macro uncertainty could lift demand for safe-haven assets.</li>
<li>Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) gained 7.3% to $38.49 following upbeat quarterly results.</li>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) gained 5.8% to $0.9257.</li>
<li>Urban Outfitters, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) rose 5.5% to $45.53. Citigroup analyst Paul Lejuez maintained Urban Outfitters with a Buy and lowered the price target from $65 to $54</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44709125/this-apple-analyst-is-no-longer-bearish-here-are-top-5-upgrades-for-wednesday">This Apple Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday</a></li>
</ul>
Photo via Shutterstock

Intraday Update

Markets

KRUS

NUTX

SMPL

URBN

Simply Good Foods, Pacific Biosciences of California, Kura Sushi, Delta Air Lines And Other Big Stocks Moving Higher On Wednesday

WIIM

Pacific Biosciences of California shares are trading higher after the company reported its Q1 prelimary revenue results.

In response to ongoing market uncertainty, PacBio is executing a plan to reduce both headcount across all functions and non-headcount related expenses to lower its annualized non-GAAP operating expense run-rate by $45 million to $50 million by year end in relation to its prior guidance of $270 million to $280 million. Following the reductions, PacBio aims to focus on its highest-impact long-read platform development initiatives.&nbsp;

Management

PacBio Says In Response To Ongoing Market Uncertainty, PacBio Is Executing A Plan To Reduce Both Headcount Across All Functions And Non-Headcount Related Expenses To Lower Its Annualized Non-GAAP Operating Expense Run-Rate By $45M-$50M

PacBio Sees Prelim. Q1 Revenue $36.9M, Reiterates 2025 Revenue Guidance

PacBio Appoints Jim Gibson As CFO, Effective Start Date Mar. 31

6 analysts have expressed a variety of opinions on Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $2.04, a high estimate of $2.50, and a low estimate of $1.50. Observing a downward trend, the current average is 30.14% lower than the prior average price target of $2.92. 
<img src="https://www.benzinga.com/files/images/story/2025/1742929238_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Pacific Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$2.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2.00</td>
<td>$2.50</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.50</td>
<td>$1.75</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.75</td>
<td>$2.25</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Pacific Biosciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pacific Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Pacific Biosciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Pacific Biosciences's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PACB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Pacific Biosciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Pacific Biosciences: A Closer Look</h2>
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
<h3>A Deep Dive into Pacific Biosciences's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Pacific Biosciences's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -32.79%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Pacific Biosciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.04% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Pacific Biosciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.49% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Pacific Biosciences's ROA stands out, surpassing industry averages. With an impressive ROA of 0.17%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.33, caution is advised due to increased financial risk.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Pacific Biosciences: Insights From 6 Financial Analysts

Scotiabank analyst Sung Ji Nam maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Sector Outperform and lowers the price target from $6 to $2.

Scotiabank Maintains Sector Outperform on Pacific Biosciences, Lowers Price Target to $2

On Friday, March 21, 2025, the Cathie Wood-led Ark Invest made some notable trades, including significant buys and sells.
Ark Invest's fund bought Iridium Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>), Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), Pacific Biosciences of California Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) and Absci Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>), while selling Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>).
The IRDM Trade: Ark Invest&#8217;s ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>), ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>), and ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) funds purchased a total of 68,355 shares of Iridium Communications Inc.
The total value of the shares bought, based on the last close price of $27.65, is approximately $1.89 million.
The BEAM Trade: Ark Invest&#8217;s ARKK and Ark Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) funds bought a total of 28,717 shares of Beam Therapeutics Inc.
The total value of the shares bought, based on the last close price of $23.3, is approximately $669,106.
The PACB Trade: Ark Invest&#8217;s ARKK fund bought a whopping 243,300 shares of Pacific Biosciences of California Inc.
The total value of the shares bought, based on the last close price of $1.3, is approximately $316,290.
Other Key Trades:
<ul>
<li>Illumina Inc: Ark Invest sold a total of 42,616 shares through ARKK and ARKG.</li>
<li>Absci Corp: Ark Invest&#8217;s bought 71,392 shares through ARKG.</li>
<li>Repare Therapeutics: Ark Invest sold 54,786 shares through ARKG.</li>
<li>Amgen Inc: Ark Invest sold 990 shares through ARKG.</li>
<li>Veeva Systems Inc: Ark Invest sold 1,322 shares through ARKG.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44434973/tesla-record-highest-trade-ins-amid-backlash-against-ceo-elon-musk-surge-in-vandalism">Tesla Record Highest Trade-Ins Amid Backlash Against CEO Elon Musk, Surge In Vandalism</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Equities

ETFs

ABSI

AMGN

ARKG

ARKK

ARKQ

ARKX

BEAM

ILMN

IRDM

RPTX

VEEV

Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen

Piper Sandler analyst David Westenberg reiterates Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Neutral and lowers the price target from $2.5 to $2.

Reiteration

Piper Sandler Reiterates Neutral on Pacific Biosciences, Lowers Price Target to $2

In the last three months, 4 analysts have published ratings on Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $2.06, a high estimate of $2.50, and a low estimate of $1.50. Experiencing a 8.44% decline, the current average is now lower than the previous average price target of $2.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1739908820_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Pacific Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.50</td>
<td>$1.75</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.75</td>
<td>$2.25</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Pacific Biosciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pacific Biosciences compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Pacific Biosciences's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Pacific Biosciences's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PACB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pacific Biosciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Pacific Biosciences</h2>
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
<h3>Pacific Biosciences: Financial Performance Dissected</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Pacific Biosciences's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -28.23% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -151.94%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -12.84%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Pacific Biosciences's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -4.1%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 2.03, Pacific Biosciences faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Pacific Biosciences Stands With Analysts

Goldman Sachs analyst Matthew Sykes maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Neutral and lowers the price target from $1.75 to $1.5.

Goldman Sachs Maintains Neutral on Pacific Biosciences, Lowers Price Target to $1.5

Stephens &amp; Co. analyst Mason Carrico reiterates Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Overweight and maintains $2.5 price target.

Stephens & Co. Reiterates Overweight on Pacific Biosciences, Maintains $2.5 Price Target

Pacific Biosciences shares are trading higher after a 13F filing showed SoftBank Group took a new stake of 20.45 million shares.

Pacific Biosciences of California shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results. Also, Softbank added 20.45M shares in the company.

<a href="https://www.sec.gov/Archives/edgar/data/1065521/000106299325002489/xslForm13F_X02/form13fInfoTable.xml" title="https://www.sec.gov/Archives/edgar/data/1065521/000106299325002489/xslForm13F_X02/form13fInfoTable.xml">https://www.sec.gov/Archives/edgar/data/1065521/000106299325002489/xslForm13F_X02/form13fInfoTable.xml</a>

BETR

DASH

IONQ

LMND

NMRA

NVDA

RXRX

SFTBY

TMUS

VTEX

WBTN

SoftBank Group 13F Update: New 14.67M Share Stake In Recursion Pharmaceuticals, 20.45M Shares In Pacific Biosciences, 628.55K Shares In Better Home & Finance; Dissolved 5.68M Shares Stake In Exscientia, 1.59M Shares In IonQ, 23.38K Shares In DoorDash; Increased Stakes in T-Mobile, Nvidia, Webtoon, VTEX, YMM; Decreased Stakes In Lemonade, Nu Holdings, Neumora, Symbotic

U.S. stocks were mostly lower, with the Dow Jones falling around 100 points on Friday.
Shares of The Goodyear Tire &amp; Rubber Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GT#NASDAQ">GT</a>) rose sharply during Friday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/GT/analyst-ratings">quarterly financial results</a>.
Goodyear Tire &amp; Rubber reported quarterly earnings of 39 cents per share which beat the analyst consensus estimate of 31 cents per share. The company reported quarterly sales of $4.95 billion which beat the analyst consensus estimate of $4.87 billion.
Goodyear Tire &amp; Rubber shares jumped 19.4% to $9.76 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>WeRide Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) shares jumped 97.7% to $33.94 after Nvidia disclosed a stake of 1.74 million shares in a 13F filing.</li>
<li>Nu Skin Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) gained 34.6% to $8.65 following upbeat quarterly earnings.</li>
<li>Udemy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UDMY#NASDAQ">UDMY</a>) gained 23.7% to $9.67 after the company reported fourth-quarter earnings and revenue above estimates.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) rose 20.9% to $1.7900 following upbeat quarterly earnings.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) gained 20.3% to $20.86.</li>
<li>Personalis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) gained 17.2% to $5.85.</li>
<li>TreeHouse Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THS#NYSE">THS</a>) gained 17% to $38.90 following fourth-quarter results.</li>
<li>Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) climbed 16% to $17.25.</li>
<li>Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) gained 15.8% to $163.43 following a quarterly revenue beat. Multiple analysts upgraded the stock following the report.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) rose 15.2% to $100.00 following better-than-expected quarterly financial results.</li>
<li>Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) gained 14.8% to $32.85.</li>
<li>CAE Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAE#NYSE">CAE</a>) rose 14.7% to $26.98 after the company reported a year-over-year increase in third-quarter financial results.</li>
<li>DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) gained 13.3% to $52.62 after the company reported better-than-expected quarterly adjusted EPS results and raised its FY25 revenue guidance.</li>
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) rose 11.2% to $221.56.</li>
<li>Pilgrim&#8217;s Pride Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPC#NASDAQ">PPC</a>) gained 9.6% to $57.07.</li>
<li>Tencent Music Entertainment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>) rose 5.3% to $13.43</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43692962/top-3-consumer-stocks-you-may-want-to-dump-in-february">Top 3 Consumer Stocks You May Want To Dump In February</a></li>
</ul>

ABNB

DKNG

PONY

PSNL

ROKU

UDMY

Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday

Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.21) by 4.76 percent. This is a 25.93 percent increase over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $39.22 million which missed the analyst consensus estimate of $40.16 million by 2.33 percent. This is a 32.79 percent decrease over sales of $58.36 million the same period last year.

Earnings Beats

Earnings Misses

Pacific Biosciences Q4 Adj $(0.20) Beats $(0.21) Estimate, Sales $39.22M Miss $40.16M Estimate

Press Releases

PacBio Announces Appointment of Chris Smith to Board of Directors

PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025

PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service

PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results

PacBio Grants Equity Incentive Award to New Employee

PacBio to Participate in TD Cowen's 45th Annual Health Care Conference

Scientists Solve One of Genomics' Biggest Challenges by Using HiFi Sequencing to Distinguish Highly Similar Paralogous Genes

Jim Gibson to join PacBio as Chief Financial Officer

PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Atlantic International Corp. - Common Stock

Atlantic International

Azenta

BioLife Solutions

Codexis

Champions Oncology

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Pacific Biosciences

ニュース

最新ニュース Pacific Biosciences (NASDAQ:PACB) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル